Innocan Pharma Corporation: Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: It Was as If a New Dog Came into Our Lives

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 24, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful

Related Keywords

Jerusalem ,Israel General ,Israel ,Herzliya ,Tel Aviv ,Canada ,Hebrew University ,Yerushalayim ,Canadian ,Iris Bincovich ,Chezy Barenholz ,Innocan Pharma ,Development Company Yissum ,Company Or Innocan ,Innocan Pharma Corporation ,Liposome Research Department ,Market Research ,Innocan Pharma Ltd ,Hebrew University Of Jerusalem ,Alberta Newsfile Corp ,Tel Aviv University ,Yissum Research ,Pharma Corporation ,Pharma Ltd ,Development Company ,Professor Chezy Barenholz ,Professor Barenholz ,Innocan ,Dharma ,Corporation ,Reports ,Uccessful ,Reclinical ,Trial ,Results ,Egarding ,Rain ,Management ,Name ,Lives ,